格列酮类药物在致癌作用中的正负效应：实验模型与临床实践

Positive and negative effects of glitazones in carcinogenesis: experimental models vs. clinical practice.

作者信息

Bojková Bianka, Orendáš Peter, Kubatka Peter, Péč Martin, Kassayová Monika, Kisková Terézia, Kajo Karol

机构信息

Department of Animal Physiology, Faculty of Science, Institute of Biology and Ecology, P.J. Šafárik University, Moyzesova 11, 041 67 Košice, Slovak Republic.

出版信息

Pathol Res Pract. 2014 Aug;210(8):465-72. doi: 10.1016/j.prp.2014.06.003. Epub 2014 Jun 19.

DOI:10.1016/j.prp.2014.06.003

PMID:25023882

Abstract

Diabetes increases cancer risk, which may be modulated by careful choice of treatment. Experimental reports showed efficacy of glitazones in various in vitro and in vivo models of carcinogenesis, but procarcinogenic effects in some models were reported too, and, similarly, data on cancer incidence in glitazone users are inconsistent. This review summarizes oncostatic effects of glitazones in preclinical and clinical studies and brings a brief summary of their impact on cancer risk in diabetic patients, with a focus on the association between pioglitazone use and bladder cancer.

摘要

糖尿病会增加患癌风险，而通过谨慎选择治疗方法或许可以对这一风险进行调节。实验报告显示，在各种体外和体内致癌模型中，格列酮类药物都有疗效，但也有报告称其在某些模型中具有促癌作用，同样，关于使用格列酮类药物的患者癌症发病率的数据也并不一致。这篇综述总结了格列酮类药物在临床前和临床研究中的抑癌作用，并简要概述了它们对糖尿病患者癌症风险的影响，重点关注吡格列酮的使用与膀胱癌之间的关联。